ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of September 11, 2026, ALGS stock price declined to $5.16 with 18,221 million shares trading.

ALGS has a beta of 1.31, meaning it tends to be more sensitive to market movements. ALGS has a correlation of 0.03 to the broad based SPY ETF.

ALGS has a market cap of $32.22 million. This is considered a Sub-Micro Cap stock.

Last quarter Aligos Therapeutics reported $0 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-19 million and exceeded earnings estimates by $1.14.

In the last 3 years, ALGS traded as high as $46.80 and as low as $3.76.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, DFMC, DFAS, DFAC.

ALGS has underperformed the market in the last year with a price return of -51.8% while the SPY ETF gained +18.6%. ALGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning 0.0% and -27.0%, respectively, while the SPY returned +5.8% and -0.7%, respectively.

ALGS support price is $5.01 and resistance is $5.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.